ArticleHeart and vessels2010
Increased plasma levels of endothelin-1 and urotensin-II in patients with coronary heart disease.
Article in Heart and vessels, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Investigating the role of acute mental stress on endothelial dysfunction: a systematic review and meta-analysis.Clinical research in cardiology : official journal of the German Cardiac Society · 2015Pooled it
- Review
- The relationship between the carotid atherosclerosis ultrasound parameters and the cardiac and endothelial functions of coronary heart disease patients.American journal of translational research · 2021Article
- Association between Plasma Urotensin II and Risk of Hypertension: Findings from a Prospective Study.International journal of hypertension · 2020Article
- Impaired frequencies and function of platelets and tissue remodeling in chronic Chagas disease.PloS one · 2019Article
- Genetic susceptibility of five tagSNPs in the endothelin-1 (Bioscience reports · 2018Article
- Endothelin-1 impairs coronary arteriolar dilation: Role of p38 kinase-mediated superoxide production from NADPH oxidase.Journal of molecular and cellular cardiology · 2015Article
- The relationship between coronary slow flow phenomenon and urotensin-II: A prospective and controlled study.Anatolian journal of cardiology · 2015Article
- Inhibition of UII/UTR system relieves acute inflammation of liver through preventing activation of NF-κB pathway in ALF mice.PloS one · 2014Article
- Urotensin-II and endothelin-I levels after contrast media administration in patients undergoing percutaneous coronary interventions.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2013Article
- Endothelin-1 prolongs intracellular calcium transient decay in neonatal rat cardiac myocytes.Heart and vessels · 2012Article
- NOX4 mediates activation of FoxO3a and matrix metalloproteinase-2 expression by urotensin-II.Molecular biology of the cell · 2011Article
- Genetics of hypertension and cardiovascular disease and their interconnected pathways: lessons from large studies.Current hypertension reports · 2011Review
- The significance of circulating endothelin-1 as a predictor of coronary artery disease status and clinical outcomes following coronary artery catheterization.Cardiovascular pathology : the official journal of the Society for Cardiovascular PathologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Research has identified the vasoconstrictors endothelin-1 (ET-1) and urotensin-II (U-II) as having a role in the development of atherosclerotic cardiovascular disease. We aimed to observe alterations in plasma levels of both ET-1 and U-II in patients with coronary heart disease (CHD) undergoing percutaneous transluminal coronary angioplasty (PTCA) and stent therapy from November 2006 through May 2007. We examined plasma levels of ET-1 and U-II in 40 patients with CHD and 40 age-matched healthy subjects by radioimmunoassay (RIA). Chi-square test, Student's t-test, and one-way analysis of variance were used for statistical analyses. Correlations between variables were tested by simple linear regression analysis. Coronary heart disease patients had significantly higher ET-1 and UII levels than healthy controls (20.05 +/- 4.65 vs 8.16 +/- 3.38 and 71.90 +/- 11.61 vs 20.89 +/- 7.00 pg/ml, respectively, all P < 0.01). Importantly, plasma levels of U-II and ET-1 were correlated in patients with CHD (r = 0.64, P = 0.01). On day 1 after PTCA and stent therapy, plasma levels of ET-1 and U-II were significantly higher, by 99% and 25%, respectively, than those before therapy (all P < 0.01). On day 3 after therapy, ET-1 levels were higher by 25% (P < 0.01) than before therapy, and U-II levels decreased rapidly and were close to baseline levels (P > 0.05). On day 7 after therapy, CHD patients had significantly lower ET-1 and U-II levels than before therapy (all P < 0.01). Since ET-1 and U-II levels may be increased in plasma of patients with CHD, their activation might have clinical significance in terms of early intervention in patients with CHD, especially after PTCA and stent therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.